论文部分内容阅读
目的探讨可溶性血管内皮细胞生长因子受体2基因(sFlk-1)转染联合泰素帝治疗耐药结直肠癌。方法随机均分40只裸鼠至A、B、C、D组,A、B组种植转sFlk-1基因的耐药结直肠癌细胞,C、D组种植耐药结直肠癌细胞,A、C组接受泰素帝(200μg/3d)治疗。70d后比较各组裸鼠瘤重,微血管密度(MVD)和凋亡情况。结果A组瘤重(0．12±0．03)g明显小于B(0．22±0．02)g和C组(1．26±0．03)g、(P＜0．01),但A、B和C组瘤重均小于D组(1．26±0．03)g、(P＜0．01)。A组MVD明显少于其他组,凋亡增加(P＜0．01)。结论sFlk-1基因和泰素帝均能抑制耐药结直肠癌生长,两者联合并非简单作用相加,而是协同增效。
Objective To investigate the expression of soluble vascular endothelial growth factor receptor 2 gene (sFlk-1) in combination with taxol in the treatment of drug-resistant colorectal cancer. Methods A total of 40 nude mice were randomly divided into groups A, B, C and D, and groups A and B were established with drug-resistant colorectal cancer cells transfected with sFlk-1. Groups C and D were established with drug-resistant colorectal cancer cells, Group C received taxotere (200μg / 3d) treatment. After 70 days, the tumor weight, microvessel density (MVD) and apoptosis in each group were compared. Results The tumor weight in group A (0.12 ± 0.03) g was significantly lower than that in group B (0.22 ± 0.02) g and group C (1.26 ± 0.03) g (P <0.01) However, the tumor weights in groups A, B and C were all less than those in group D (1.26 ± 0.03) g (P <0.01). MVD in group A was significantly less than that in other groups, and apoptosis increased (P <0.01). Conclusion Both sFlk-1 gene and taxotere can inhibit the growth of drug-resistant colorectal cancer. The combination of the two is not a simple addition, but a synergistic effect.